GRAIL, Inc.

GRAL Healthcare Diagnostics & Research

GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024.

Revenue
+3.71%
EPS
+10.2%
Free cash flow
−24.9%

Quarter to September 2026, against a year earlier

119.26 0.13 +0.11%
Market cap
$5.3B
P/E
0.0×
Fwd P/E
−14.5×
Dividend yield
—
F-score
6/9
Altman Z
0.37
Beneish M
n/a
Dividend safety
n/a

GRAIL, Inc. (GRAL) P/S ratio

Alert me on P/S ratio

As of 5 November 2026, GRAIL, Inc. (GRAL) trades at a P/S ratio of 34.9×. Over the past ten years it has ranged from 0.0× (June 2024) to 44.6× (October 2026); the current reading is higher than 96% of that period. That is above the Diagnostics & Research industry median of 4.2× and above the Healthcare sector median of 3.5×.

P/S ratio, daily

Embed this chart

Annual newest first

Period P/S ratio Change
FY2025 21.4× 371.44%
FY2024 4.5× —
FY2023 0.0× —
FY2022 0.0× —

Quarterly newest first

Period P/S ratio Change
Sep 2026 39.3× 120.90%
Jun 2026 17.8× 32.38%
Mar 2026 13.5× (37.06%)
Dec 2025 21.4× 41.92%
9 more quarters

Against its own ten years

Low 0.0× High 44.6×
Ten-year median 11.3×
Current reading's percentile 96

P/S ratio against peers

Company P/S ratio
ICLR ICON PLC compare 1.9×
RDNT RadNet, Inc. compare 2.7×
VCYT Veracyte, Inc. compare 3.3×
SHC Sotera Health Company compare 3.7×
QGEN QIAGEN N.V. compare 5.0×
CDNA CareDx, Inc. compare 8.1×
BLLN BillionToOne, Inc. compare 12.1×
ADPT Adaptive Biotechnologies Corporation compare 14.5×
GRAL GRAIL, Inc. 34.9×
Diagnostics & Research industry median 4.2×
Healthcare sector median 3.5×
Market median 1.9×

What P/S ratio is

Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.

(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)

The full definition of P/S ratio →

More on GRAL